Ontario Update
Ontario Drug Benefit (ODB) Formulary / Comparative Drug Index (Formulary) has been updated and becomes effective February 28, 2017.
See Ontario’s Drug Benefit Formulary
New Single Source Drug Products
Daklinza (daclatasvir) 30mg, 60mg Tab (BMS)
Epclusa (sofosbuvir / velpatasvir) 400mg/100mg Tab (GIL)
Sunvepra (asunaprevir) 100mg Tab (BMS)
Zepatier (elbasvir / grazoprevir) 50mg/100mg Tab (MEK)
Transition from Exceptional Access Program (EAP) to Limited Use (LU)
Ibavyr (ribavirin) 200mg, 400mg, 600mg Tab (PEN)
Sovaldi (sofosbuvir) 400mg Tab (GIL)
Harvoni (ledipasvir / sofosbuvir) 90mg/400mg Tab (GIL)
To receive updates similar to this one please be sure to sign up for Market Access Signals, our free e-mail newsletter service.
